Cefazolin-Ertapenem Combination Accelerates Clearance in Persistent MSSA Bacteraemia
Persistent MSSA bacteraemia remains one of the most dangerous bloodstream infections in hospital practice because every extra day of positive cultures increases concern for metastatic seeding, endocarditis, and ongoing endothelial injury. In a ten-year multicentre retrospective cohort from two Queensland tertiary hospitals, cefazolin plus ertapenem shortened the time to sterilisation compared with standard care in a matched analysis, offering clinical support for a drug combination that has already shown biologic synergy in preclinical work and small clinical series.
The signal was not subtle in the subgroup that actually received the combination before the first negative blood culture. Among 14 patients treated in that window, median time to sterilisation was 1 day, compared with 2 days in the matched non-combination group.
Why a Dual-Beta-Lactam Strategy May Work Against Stubborn MSSA
The rationale for combining cefazolin and ertapenem rests on bacterial physiology rather than broad-spectrum brute force. Staphylococcus aureus can persist in the bloodstream through inoculum effects, high bacterial burden, and a capacity to occupy protected niches where monotherapy struggles to sterilise rapidly. Dual beta-lactam exposure may increase killing through complementary binding to penicillin-binding proteins and improved suppression of cell wall synthesis, a plausible explanation for the faster culture clearance seen here.
This matters most when bacteremia refuses to break. Persistent positivity is not only a microbiologic endpoint; it is a marker of unsettled infection biology, where the bloodstream remains a conduit for dissemination to valves, bones, joints, and implanted material. Faster clearance does not prove better long-term outcomes on its own, but it changes the bedside tempo of care, especially when clinicians are trying to decide whether source control is adequate and whether occult infection is still active.
Cohort Size, Matching, and the Sterilisation Endpoint
Investigators reviewed all adults with persistent MSSA bacteraemia at the two hospitals between January 2014 and December 2024, identifying 288 episodes in 283 patients. Twenty-six patients received cefazolin-ertapenem combination therapy, and 14 of those started treatment before the first negative blood culture, allowing direct comparison with a matched non-combination cohort.
In the matched analysis, the faster sterilisation advantage persisted beyond the simple median comparison. Cox regression in the matched cohort of 114 patients showed an increased rate of blood culture clearance with combination therapy, with a hazard ratio of 1.8, 95% confidence interval 1.2 to 2.7, and P = 0.004. In practical terms, cultures cleared sooner in the combination arm, and that difference was large enough to survive adjustment within the retrospective design.
The endpoint is clinically meaningful because duration of bacteremia often drives downstream decisions. Infectious diseases teams watch serial cultures closely to judge whether the chosen regimen is working, whether a hidden focus remains in place, and whether escalation or source intervention is still needed. A shorter interval to sterilisation can reduce uncertainty during a high-risk window when a patient may still be febrile, unstable, or at risk for embolic complications.
Mortality and Relapse Did Not Separate the Groups
The faster microbiologic response did not translate into a detectable difference in the larger clinical outcomes captured in this dataset. Ninety-day all-cause mortality was 20.0% in the combination group and 23.0% in the comparator group, with P = 0.73. Ninety-day relapse rates were 11.5% and 8.3%, respectively, with P = 0.57.
Those findings are a reminder that bloodstream sterilisation is only one part of the story in invasive staphylococcal infection. Patients with persistent MSSA bacteraemia often carry a heavy burden of comorbidity, difficult source control, and deep-seated infection, and those factors may dominate the mortality curve even if a regimen clears blood cultures more quickly. Relapse, too, depends on whether the original nidus was truly removed or merely suppressed.
A one-day median advantage is valuable, but it is not yet proof of survival benefit.
Safety Signals Were Actively Tracked, but the Clinical Tradeoff Remains Unresolved
The secondary outcomes included development of multi-resistant organisms, Clostridioides difficile infection, and adverse drug events. Those were appropriate surveillance measures for a strategy that adds a broad-spectrum carbapenem to a first-line anti-staphylococcal beta-lactam, since every escalation in antimicrobial intensity raises stewardship questions alongside efficacy questions.
Even so, the core clinical tradeoff remains centered on a familiar dilemma in severe infection care: speed versus exposure. A regimen that clears bacteremia faster may reduce the period of uncontrolled infection, but broader coverage can also increase selective pressure on gut flora and complicate stewardship goals if used indiscriminately. For that reason, the combination is best interpreted as a targeted escalation for persistent bacteremia rather than a replacement for standard therapy.
What This Means for Hospital Practice Today
The data support a cautious, clinically grounded interpretation. In persistent MSSA bacteraemia, cefazolin-ertapenem was associated with faster blood culture sterilisation in a matched cohort and showed no obvious penalty in the measured safety outcomes reported in the abstract. The study’s size still leaves uncertainty around the harder endpoints that matter most to patients and hospitals, especially death and relapse.
Because this was a retrospective review across two centers, treatment selection was not random and unmeasured confounding may have shaped who received combination therapy. Patients started on the dual regimen may have differed in severity, source burden, timing of specialist review, or parallel source control procedures in ways that are not fully captured by the abstract. Even with matching and regression, observational data cannot settle the question of causality.
Prospective randomised evaluation is the logical next step. Until then, the most defensible reading is straightforward: in persistent MSSA bacteraemia, cefazolin plus ertapenem appears to accelerate microbiologic clearance, and that acceleration may be clinically useful when the bloodstream is still positive despite standard treatment. Whether that faster clearance can be converted into better survival, fewer relapses, or more efficient care pathways remains the central unanswered question for a trial designed around patient-centered outcomes rather than culture time alone.